PBYI vs AZN vs PFE vs IQV vs MCK

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Puma Biotechnology, Inc. (PBYI) offers the better valuation at 11. 9x trailing P/E (29. 0x forward), making it the more compelling value choice. Analysts rate Puma Biotechnology, Inc. (PBYI) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Puma Biotechnology, Inc.

(PBYI) is the cheapest at 11. 9x versus McKesson Corporation at 29. 2x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus AstraZeneca PLC's 0. 81x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -25. 8% for Puma Biotechnology, Inc. (PBYI). Over 10 years, the gap is even starker: MCK returned +348. 1% versus PBYI's -70. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 2991% more volatile than MCK relative to the S&P 500. On balance sheet safety, Puma Biotechnology, Inc. (PBYI) carries a lower debt/equity ratio of 22% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AstraZeneca PLC (AZN) is the more profitable company, earning 17.

5% net margin versus 0. 9% for McKesson Corporation — meaning it keeps 17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus 1. 2% for MCK. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus AstraZeneca PLC's 0. 81x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 9x forward P/E versus 29. 0x for Puma Biotechnology, Inc. — 20. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MCK: 33. 8% to $1006. 50.

In this comparison, PFE (6.

5% yield), AZN (1. 8% yield), MCK (0. 4% yield) pay a dividend. PBYI, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +348. 1% 10Y return). Both have compounded well over 10 years (MCK: +348. 1%, IQV: +166. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PBYI is a small-cap deep-value stock; AZN is a large-cap quality compounder stock; PFE is a mid-cap income-oriented stock; IQV is a mid-cap quality compounder stock; MCK is a mid-cap high-growth stock. AZN, PFE pay a dividend while PBYI, IQV, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.